Announcements Trials

Browse Landscape

Phase

Phase NA 1 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Prostatic Neoplasms 3 Pancreatic Neoplasms 3 Hemangioma 3 Urinary Bladder Neoplasms 2 Sarcoma, Kaposi 2 Sarcoma 2 Multiple Myeloma 2 Melanoma 2 Hemangiosarcoma 2 Hemangioma, Cavernous, Central Nervous System 2 Breast Neoplasms 2 Urethral Neoplasms 1 Ureteral Neoplasms 1 Tuberous Sclerosis 1 Triple Negative Breast Neoplasms 1 Stomach Neoplasms 1 Recurrence 1 Ovarian Neoplasms 1 Neuroblastoma 1 Neoplasms 1 Neoplasm Metastasis 1 Liver Neoplasms 1 Kidney Neoplasms 1 Histiocytoma, Malignant Fibrous 1 Digestive System Neoplasms 1 Colorectal Neoplasms 1 Colonic Neoplasms 1 Cholangiocarcinoma 1 Carcinoma, Transitional Cell 1 Carcinoma, Renal Cell 1

Interventions

Paclitaxel 134 Carboplatin 129 Bevacizumab 86 Gemcitabine 45 pembrolizumab 37 olaparib 33 Cisplatin 30 liposomal doxorubicin 29 Docetaxel 29 Cyclophosphamide 29 Topotecan 28 niraparib 27 Taxes 20 Etoposide 18 Filgrastim 16 Doxorubicin 16 Immunoglobulin G 15 Disulfides 15 apatinib 12 Letrozole 12 Albumin-Bound Paclitaxel 12 Drug Therapy 11 fluzoparib 10 fludarabine 10 Specimen Handling 10 Magnetic Resonance Spectroscopy 10 Biopsy 10 durvalumab 9 Nivolumab 9 pazopanib 8

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Ovarian Neoplasms × Propranolol × Clear all

NCT06839144 2025-07-11

OC-POP-PT

Tel-Aviv Sourasky Medical Center

Phase 2 Recruiting

Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡